Home / Going-concern warnings / CytomX Therapeutics, Inc.
Filed 2025-05-12 路 Form 10-Q 路 Accession 0000950170-25-068511 micro
Price before filing: $0.9284 (2025-05-09 close, split/dividend-adjusted)
Market cap at flag: $274.9M (2025-05-12) 路 Latest: $499.2M (2026-10-16)
| Window | CTMX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +203.7% | +6.6% | +197.2% | 2025-06-11 |
| 90 days | +148.8% | +13.0% | +135.8% | 2025-08-11 |
| 180 days | +351.3% | +21.4% | +329.9% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 5 insiders sold $48K (5 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-03-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 19,512 | $0.60 | $12K | no | Form 4 |
| 2025-03-18 | Chu Yu-Waye Chief Medical Officer | Sale | 4,025 | $0.60 | $2K | no | Form 4 |
| 2025-03-18 | McCarthy Sean A. CEO, Director | Sale | 37,656 | $0.60 | $23K | no | Form 4 |
| 2025-03-18 | Ogden Christopher Chief Financial Officer | Sale | 8,551 | $0.60 | $5K | no | Form 4 |
| 2025-03-18 | ROWLAND LLOYD A General Counsel | Sale | 10,203 | $0.60 | $6K | no | Form 4 |
| 2025-05-12: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-02-11 to 2025-06-11. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"Our recurring losses from operations and negative cash flows have raised substantial doubt regarding our ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.